Ubs Asset Management Americas Inc Nurix Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 128,524 shares of NRIX stock, worth $2.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

128,524

Previous 128,671 0.11%

Holding current value

$2.83 Million

Previous $2.69 Million 7.45%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$18.93 - $25.69 $2,782 - $3,776	-147 Reduced 0.11%	128,524 $2.89 Million
Q2 2024 Aug 13, 2024	BUY	$12.02 - $21.3 $1.55 Million - $2.74 Million	128,671 New	128,671 $2.69 Million
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $47,969 - $61,518	-6,103 Reduced 2.47%	240,608 $1.89 Million
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $10,400 - $16,110	1,215 Added 0.49%	246,711 $2.19 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $146,953 - $217,449	14,904 Added 6.46%	245,496 $2.7 Million
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $169,081 - $271,654	-13,713 Reduced 5.61%	230,592 $3 Million
Q2 2022 Aug 12, 2022	SELL	$7.88 - $14.82 $70,659 - $132,890	-8,967 Reduced 3.54%	244,305 $3.1 Million
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $331,496 - $759,573	-25,618 Reduced 9.19%	253,272 $3.55 Million
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $190,533 - $248,710	-7,209 Reduced 2.52%	278,890 $8.07 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $4,973 - $8,035	219 Added 0.08%	286,099 $8.57 Million
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $6.92 Million - $10.3 Million	285,880 New	285,880 $7.58 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Nurix Therapeutics, Inc. Transaction History